Filing Details
- Accession Number:
- 0001209191-21-021293
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-03-17 16:00:26
- Reporting Period:
- 2021-03-15
- Accepted Time:
- 2021-03-17 16:00:26
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1645460 | Cue Biopharma Inc. | CUE | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1571862 | Kenneth Pienta | C/O Cue Biopharma, Inc. 21 Erie Street Cambridge MA 02139 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-03-15 | 13,000 | $5.00 | 15,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-03-15 | 13,000 | $15.10 | 2,000 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-03-16 | 439 | $5.00 | 2,439 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-03-16 | 439 | $15.09 | 2,000 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2021-03-15 | 13,000 | $0.00 | 13,000 | $5.00 |
| Common Stock | Stock Option (right to buy) | Disposition | 2021-03-16 | 439 | $0.00 | 439 | $5.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 134,006 | 2024-04-17 | No | 4 | M | Direct | |
| 133,567 | 2024-04-17 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.72, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.05 to $15.22, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4.
- The option, representing a right to purchase a total of 150,000 shares, vests in four equal annual installments beginning December 31, 2017.
Billionaire Hedge Funds
